What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open‐ended survey responses
Open Access
Abstract
Background: Accurate variant classification and relaying reclassified results to patients is critical for hereditary cancer care delivery. Over a 5‐ to 10‐year period, 6%–15% of variants undergo reclassification. As the frequency of reclassifications increases, the issue of whether, how, when, and which providers should recontact patients becomes important but remains contentious.Methods: The authors used inductive thematic analysis to analyze open‐ended comments offered by oncologists and genetic counselors (GCs) from a large national survey.Results: Of the 634 oncologists and cancer GCs, 126 (20%) offered substantive free‐text comments. Four thematic areas emerged: 1) ambiguity over professional responsibility to recontact, 2) logistical challenges with recontact, 3) importance of inter‐institutional communication, and 4) suggested solutions. Some oncologists felt that laboratories, not them, are responsible for recontact; others believed that ordering providers/GCs were responsible; GCs readily acknowledged their own responsibility in recontact but added important caveats. Besides the lack of up‐to‐date patient contact information, providers raised unique challenges with recontact: financial instability of laboratories, lack of clinical resources, contacting family members, and accumulating burden of reclassifications. There were numerous calls for developing practice guidelines on prioritizing variants for recontact and discussion on whether duty for recontact may be fulfilled via unidirectional, low touch modalities. Potential solutions to recontact including national databases and patient facing databases were discussed.Conclusions: The authors confirm previous themes of stakeholder opinions and add previously unreported contextual details to qualify those themes. Clarifying provider responsibilities through professional guidelines for reclassification and recontact addressing the subthemes identified here will better serve all constituencies.Keywords
This publication has 27 references indexed in Scilit:
- A multicenter study of clinical impact of variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genesCancer Medicine, 2022
- Moving toward more consistency in variant classification and clinical actionGenetics in Medicine, 2022
- Analysis of hereditary cancer gene variant classifications from ClinVar indicates a need for regular reassessment of clinical assertionsHuman Mutation, 2022
- Challenges of variant reinterpretation: Opinions of stakeholders and need for guidelinesGenetics in Medicine, 2022
- Reclassification of clinically-detected sequence variants: Framework for genetic clinicians and clinical scientists by CanVIG-UK (Cancer Variant Interpretation Group UK)Genetics in Medicine, 2022
- Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptakeGynecologic Oncology, 2022
- Management of amended variant classification laboratory reports by genetic counselors in the United States and Canada: An exploratory studyJournal of Genetic Counseling, 2021
- Patient perspectives on variant reclassification after cancer susceptibility testingMolecular Genetics & Genomic Medicine, 2020
- Prevalence of Variant Reclassification Following Hereditary Cancer Genetic TestingJAMA, 2018
- A 'joint venture' model of recontacting in clinical genomics: challenges for responsible implementationEuropean Journal of Medical Genetics, 2017